Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

计划状态

招聘

阶段

第二阶段

允许先接受免疫治疗

没有

CRC 指导的试验

药物

ABBV-400, Bevacizumab, fluorouracil, Folinic acid, Irinotecan

标签

MSS/ MMRp

评论

Phase II trial for patients with metastatic CRC who progressed on only one first-line systemic treatment (trial to consider before starting 2nd line treatment for the metastatic setting).
Only for MSS patients, no BRAF mutation allowed.
Combination of a novel agent at different doses, with different combinations of standard of care treatment.

ABBV-400: ADC (antibody-drug conjugate). C -Met–targeting antibody telisotuzumab conjugated to a potent topoisomerase 1 inhibitor (Top1i) payload.
Standard of care drugs used in combinations in this trial:  Fluorouracil, Folinic Acid, Bevacizumab

地点 位置状态
美国
Mayo Clinic Arizona /ID# 262610
亚利桑那州凤凰城 85054
招聘
Highlands Oncology Group, PA /ID# 259424
阿肯色州斯普林代尔 72762
已完成
City of Hope National Medical Center /ID# 257576
加利福尼亚州杜阿尔特 91010
招聘
City of Hope Orange County Lennar Foundation Cancer Center /ID# 268365
Irvine, California 92618
招聘
Yale School of Medicine /ID# 257494
New Haven, Connecticut 06519
招聘
Mayo Clinic /ID# 262609
佛罗里达州杰克逊维尔 32224
招聘
University of Illinois at Chicago /ID# 257300
Chicago, Illinois 60607
招聘
Northwestern University Robert H. Lurie Comprehensive Cancer Center /ID# 260563
Chicago, Illinois 60611-2927
招聘
Fort Wayne Medical Oncology and Hematology- South Office /ID# 259601
Fort Wayne, Indiana 46804
招聘
Indiana University Melvin and Bren Simon Cancer Center /ID# 258789
Indianapolis, Indiana 46202-5116
招聘
Community Health Network, Inc. /ID# 257078
Indianapolis, Indiana 46250-2042
招聘
Comprehensive Cancer Centers of Nevada /ID# 257642
Henderson, Louisiana 89052
招聘
Mayo Clinic - Rochester /ID# 257301
Rochester, Minnesota 55905-0001
招聘
Levine Cancer Institute /ID# 258840
Charlotte, North Carolina 28204
招聘
Duke Cancer Center /ID# 257236
Durham, North Carolina 27710-3000
招聘
Oregon Health & Science University, Knight Cancer Institute- /ID# 259190
俄勒冈州波特兰 97239
招聘
Medical University of South Carolina /ID# 258486
南卡罗来纳州查尔斯顿 29425
招聘
Avera Cancer Institute /ID# 257949
Sioux Falls, South Dakota 57105
招聘
MD Anderson Cancer Center /ID# 258713
德克萨斯州休斯顿 77030
招聘
Millennium Research and Clinical Development /ID# 257780
Houston, Texas 77090-3063
招聘
Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 257448
弗吉尼亚州费尔法克斯 22031
招聘
Virginia Cancer Specialists - Fairfax /ID# 257261
弗吉尼亚州费尔法克斯 22031
招聘
比利时
Imelda Ziekenhuis /ID# 257082
Bonheiden, Antwerpen 2820
招聘
Universitair Ziekenhuis Antwerpen /ID# 257080
Edegem, Antwerpen 2650
招聘
Cliniques Universitaires UCL Saint-Luc /ID# 257081
Bruxelles, Bruxelles-Capitale 1200
招聘
UZ Gent /ID# 257083
Gent, Oost-Vlaanderen 9000
招聘
Universitair Ziekenhuis Leuven /ID# 257079
Leuven, Vlaams-Brabant 3000
招聘
AZ-Delta /ID# 257084
Roeselare, West-Vlaanderen 8800
招聘
Institut Jules Bordet /ID# 257625
Anderlecht 1070
招聘
德国
Universitatsklinikum Mannheim /ID# 257781
Mannheim, Baden-Wuerttemberg 68167
招聘
Universitaetsklinikum Tuebingen /ID# 258780
Tübingen, Baden-Wuerttemberg 72076
招聘
Universitaetsklinikum Ulm /ID# 257783
Ulm, Baden-Wuerttemberg 89081
招聘
Universitaetsklinikum Carl Gustav Carus Dresden /ID# 257787
Dresden, Sachsen 01307
招聘
Charite Universitaetsklinikum Berlin - Campus Virchow /ID# 257785
柏林 13353
招聘
Universitaetsklinikum Hamburg-Eppendorf /ID# 257782
汉堡 20246
招聘
以色列
Rambam Health Care Campus /ID# 257344
Haifa, H_efa 3109601
招聘
Meir Medical Center /ID# 257089
Kfar Saba, HaMerkaz 4428164
招聘
The Chaim Sheba Medical Center /ID# 257312
Ramat Gan, Tel-Aviv 5265601
招聘
Tel Aviv Sourasky Medical Center /ID# 257090
Tel Aviv, Tel-Aviv 6423906
招聘
Shaare Zedek Medical Center /ID# 259253
Jerusalem, Yerushalayim 91031
招聘
Hadassah /ID# 257088
Jerusalem, Yerushalayim 91120
招聘
Assuta Medical Center /ID# 267581
Tel Aviv 6789140
招聘
日本
Aichi Cancer Center Hospital /ID# 257286
Nagoya-shi, Aichi 464-8681
招聘
National Cancer Center Hospital East /ID# 257282
千叶县柏市 277-8577
招聘
Kyoto University Hospital /ID# 257287
Kyoto-shi, Kyoto 606-8507
招聘
Shizuoka Cancer Center /ID# 257288
静冈县顺藤郡 411-8777
招聘
National Cancer Center Hospital /ID# 257284
104-0045 东京都中央区
招聘
大韩民国
Chonnam National University Hwasun Hospital /ID# 258366
Hwasun-gun, Jeonranamdo 58128
招聘
Seoul National University Hospital /ID# 257493
Seoul, Seoul Teugbyeolsi 03080
招聘
Asan Medical Center /ID# 257845
Seoul, Seoul Teugbyeolsi 05505
招聘
Samsung Medical Center /ID# 257571
Seoul, Seoul Teugbyeolsi 06351
招聘
Yonsei University Health System Severance Hospital /ID# 257492
首尔 03722
招聘
西班牙
Hospital Universitario Vall d'Hebron /ID# 257383
巴塞罗那 08035
招聘
Hospital Universitario 12 de Octubre /ID# 257384
马德里 28041
招聘
Hospital Universitario HM Sanchinarro /ID# 258549
马德里 28050
招聘
Hospital Clinico Universitario de Valencia /ID# 257385
巴伦西亚 46010
招聘
Hospital Universitario Miguel Servet /ID# 257388
Zaragoza 50009
招聘
台湾
Kaohsiung Chang Gung Memorial Hospital /ID# 257675
Kaohsiung City, Kaohsiung 833
招聘
National Taiwan University Hospital /ID# 257639
Taipei City, Taipei 100
招聘
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 257637
Kaohsiung 807
招聘
National Cheng Kung University Hospital /ID# 257638
Tainan 704
招聘
Taipei Veterans General Hosp /ID# 257636
台北 11217
招聘
Linkou Chang Gung Memorial Hospital /ID# 257640
Taoyuan City 333
招聘

联系方式

ABBVIE CALL CENTER
联系
844-663-3742 abbvieclinicaltrials@abbvie.com

纳入标准

纳入标准

* Diagnosis of histologically or cytologically confirmed unresectable metastatic colorectal cancer (mCRC).
* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
* Progressed on only one first-line (1L) systemic treatment of combination chemotherapy in the metastatic setting with or without targeted therapy.

排除标准

排除标准:

* Harbor the BRAF V600E mutation.
* dMMR+/MSI-H.
* Received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 28 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of ABBV-400.

NCT ID

NCT06107413

添加审判日期

2023-10-30

更新日期

2025-05-22